H.C.B. Inc.

HCB (Happy Child Birth) is a Japanese clinical-stage biotechnology company dedicated to improving the safety and efficacy of labor and delivery. Founded as a spin-off from the University of Tokyo and St. Marianna University School of Medicine, the company focuses on developing HCB-101, a novel and highly selective oxytocin receptor agonist. This lead candidate aims to provide a more controlled method for labor induction and augmentation, potentially reducing the risks of uterine hyperstimulation and subsequent fetal distress. By optimizing uterine contraction management, HCB seeks to lower the rates of emergency cesarean sections and improve overall maternal and neonatal outcomes. The company is currently advancing its clinical programs within the Japanese regulatory framework while exploring global development opportunities.